Charles Bennett to Plasma Exchange
This is a "connection" page, showing publications Charles Bennett has written about Plasma Exchange.
Connection Strength
0.404
-
Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015 Oct; 55(10):2321-30.
Score: 0.122
-
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb; (112):S20-4.
Score: 0.078
-
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007 Sep 18; 50(12):1138-43.
Score: 0.071
-
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb; 35(2):533-7.
Score: 0.055
-
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000 Jun 15; 342(24):1773-7.
Score: 0.043
-
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion. 2017 08; 57(8):2045-2053.
Score: 0.035